ArticleAntimicrobial agents and chemotherapy2018
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed, 3 syntheses or guidelines pooled it, 241 citations in OpenAlex.
- Methods for skin load reduction of Candida auris: a systematic review.Antimicrobial resistance and infection control · 2026Pooled it
- Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Global characteristics and trends in research onFrontiers in microbiology · 2023Pooled it
- Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida aurisAntimicrobial agents and chemotherapy · 2023Trial
- Micafungin microevolution inVirulence · 2026Article
- FKS1/2-variant independent mechanisms underlying the emergence of resistance in echinocandin-refractory Candida auris infections.Nature communications · 2026Article
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Antifungal resistance: from classical mechanisms to the expanding role of acetyltransferases.Journal of biomedical science · 2026Review
- Evaluation of Sensititre YeastOne for antifungal susceptibility testing ofJournal of clinical microbiology · 2026Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Article
- Wastewater intelligence predicts the emergence of clinically-relevant and drug-resistant Candidozyma auris at healthcare facilities.Nature communications · 2026Article
- Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- Review
- Review
- Rapid quantification of both fungal abundance and drug resistance via reaction kinetics.Nature biomedical engineering · 2026Article
- First report of Candidozyma auris in Vietnam.BMC microbiology · 2026Article
- Digital CRISPR-based diagnostics for quantification of Candida auris and resistance mutations.Nature biomedical engineering · 2026Article
- Comparative assessment of the broth microdilution and VITEK 2 systems for antifungal susceptibility testing of Candida auris (Candidozyma auris) Isolates.BMC microbiology · 2026Article
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.